Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Financial Flexibility Index

Latest as of March 2026: -0.01x

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Financial Flexibility Index of -0.01x as of March 2026. Free cash flow of $-91.25K (operating CF $-91.25K minus capex $0.00) represents 0% of total liabilities ($7.39 Million).

Financial Flexibility Index

-0.01x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-91.25K
Operating CF − Capex

Total Liabilities

$7.39 Million
USD

Capital Expenditures

$0.00
USD

Drugs Made In America Acquisition Corp. Ordinary Shares Financial Flexibility Index (2024–2025)

Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Ordinary Shares across 2 annual periods. See DMAA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)

Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Ordinary Shares. For the full company profile including market capitalisation, see how much is Drugs Made In America Acquisition Corp. worth.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.07x $-539.19K $-539.19K $7.28 Million ▲ +100.0%
2024 -216.50x $-172.26K $-172.26K $795.67
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities